558. Deputy Billy Kelleher asked the Minister for Health his views that the new medicines pricing agreement will act as a biosimilars blocker, due to a clause which states that biologics will only be reimbursed at a price 30% less than the current level, and only when competitor biosimilar medicines enter the market; his further views that this cannot occur, as biosimilars will financially be prevented from entering the market, as it would be unsustainable to lower their price further; and if he will make a statement on the matter. [21014/16]

Summary

558. Deputy Billy Kelleher asked the Minister for Health his views that the new medicines pricing agreement will act as a biosimilars blocker, due to a clause which states that biologics will only be reimbursed at a price 30% less than the current level, and only when competitor biosimilar medicines enter the market; his further views that this cannot occur, as biosimilars will financially be prevented from entering the market, as it would be unsustainable to lower their price further; and if he will make a statement on the matter. [21014/16]

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

1 official file

• Medicinal Products Prices

  xml · EN · 12 July 2016

  ViewDownloadOpen at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.